BioCentury | Nov 13, 2018
Distillery Techniques

Disease models

...Ltd. has TAK-063, an oral inhibitor of PDE-10A, in Phase II testing for schizophrenia. DESCRIPTION: MicroRNA-137 (miR-137)-deficient...
...University School of Medicine, Atlanta, Ga. email: peng.jin@emory.edu Chris Lieu Chinese Academy of Sciences Emory University School of Medicine MicroRNA-137 (miR-137) Phosphodiesterase-10A...
BioCentury | Sep 27, 2017
Distillery Techniques

Biomarkers

...could investigating the functional consequences of miR-137 deficiency in models of schizophrenia. DESCRIPTION: SNPs near microRNA-137 (miR-137)...
...Chicago, Ill. email: p-penzes@northwestern.edu CONTACT: Jubao Duan, NorthShore University HealthSystem, Evanston, Ill. email: jduan@uchicago.edu Winnie Pong Northwestern University MicroRNA-137 (miR-137) Schizophrenia...
BioCentury | Oct 27, 2011
Distillery Therapeutics

Indication: Neurology

...Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Alzheimer's disease (AD) MicroRNA-137 (miR-137); miR-181c; serine...
Items per page:
1 - 3 of 3